Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 62.86M P/E - EPS this Y 46.30% Ern Qtrly Grth -
Income -26.3M Forward P/E -2.58 EPS next Y 14.90% 50D Avg Chg -14.00%
Sales 895.48k PEG - EPS past 5Y - 200D Avg Chg -34.00%
Dividend N/A Price/Book 6.29 EPS next 5Y - 52W High Chg -63.00%
Recommedations 2.30 Quick Ratio 0.80 Shares Outstanding 21.89M 52W Low Chg 29.00%
Insider Own 21.63% ROA -93.42% Shares Float 18.39M Beta 0.24
Inst Own 1.06% ROE -303.20% Shares Shorted/Prior 301.54K/317.05K Price 4.11
Gross Margin 56.92% Profit Margin - Avg. Volume 25,011 Target Price 5.00
Oper. Margin -3,068.71% Earnings Date May 13 Volume 36,528 Change 0.49%
About Mainz Biomed N.V.

Mainz Biomed N.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics. It offers ColoAlert, a colorectal cancer screening stool-based deoxyribonucleic acid test; and PancAlert, a product candidate for a pancreatic cancer screening test. The company has a research collaboration with Microba Life Sciences to discover and develop novel therapeutics for major diseases. The company was founded in 2008 and is based in Mainz, Germany.

Mainz Biomed N.V. News
04/29/24 mRNA Is Promising A Breakthrough In Fighting Cancer
04/25/24 Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
04/10/24 The Pharmaceutical Industry Finds Itself At A Historical Crossroads
04/09/24 Mainz Biomed Reports Full Year 2023 Financial Results
03/19/24 Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
03/18/24 Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
03/12/24 Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
03/08/24 What Makes Mainz Biomed NV (MYNZ) a New Buy Stock
03/05/24 Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
02/28/24 Gynecology Plays A Pivotal Role In Colorectal and Endometrial Cancer Screening
02/27/24 Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community
02/22/24 Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
02/22/24 Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®
02/21/24 Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
02/07/24 2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front
02/06/24 Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany
02/01/24 Pfizer Surprises With Profit But Revolutionizing Cancer Treatment Is Its Best Chance Of Getting Back In The Saddle
01/11/24 Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium
01/09/24 2024 Marks a New Era Of Pharmaceutical Innovation
01/09/24 Mainz Biomed Provides Year-End Corporate Review 2023
MYNZ Chatroom

User Image GuntherB Posted - 3 hours ago

$MYNZ It looks like they won't make it sadly. Amazing product which almost nobody in Europe is aware of.

User Image Destructor Posted - 7 hours ago

$MYNZ

User Image Tbio64 Posted - 1 day ago

$MYNZ wtf.... always down

User Image Destructor Posted - 1 day ago

$MYNZ free fall

User Image Tbio64 Posted - 2 days ago

$MYNZ c m on give me sum real good news....

User Image Tbio64 Posted - 2 days ago

$MYNZ wtf let's go....

User Image bo7 Posted - 2 days ago

$MYNZ look at this chart..

User Image Tbio64 Posted - 04/26/24

$MYNZ new 52w low wtf....

User Image Destructor Posted - 04/26/24

$MYNZ sec please investigate

User Image Orlandotrader Posted - 04/25/24

$MYNZ Hence these results represent a critical milestone on our path to launching our FDA PMA pivotal study ReconAAsense, which is planned to recruit up to 15,000 patients.”

User Image Orlandotrader Posted - 04/25/24

$MYNZ Subject to a positive outcome of the FDA PMA study, Mainz Biomed’s innovative next generation test has the potential to disrupt the at-home CRC diagnostic screening market by providing the most robust and accurate test and become new gold standard.

User Image Orlandotrader Posted - 04/25/24

$MYNZ Not gonna be able to hold this down forever. Better product than ColoGuard marketed by ExactScience. After Pivotal US trial this Summer Suitor will come knocking

User Image Tbio64 Posted - 04/25/24

$MYNZ new atl.... No new ath ??

User Image Tbio64 Posted - 04/25/24

$MYNZ positiv News and down we go.??? What's wrong here??

User Image SBW_Trades Posted - 04/25/24

$MYNZ positive news here

User Image hsfjhv Posted - 04/25/24

$MYNZ lets goooo

User Image alex_j_durden Posted - 04/25/24

$MYNZ WoW what a dip buy! Thank you!! 👏👏👏

User Image Orlandotrader Posted - 04/25/24

$MYNZ Highly Manipulated

User Image hsfjhv Posted - 04/25/24

$MYNZ great news

User Image TheTradeXchange Posted - 04/25/24

$MYNZ Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic

User Image harristradez Posted - 04/25/24

$MYNZ news 📰

User Image Stock_Titan Posted - 04/25/24

$MYNZ Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic https://www.stocktitan.net/news/MYNZ/mainz-biomed-reports-positive-topline-results-from-pooled-study-wxnqajajrikw.html

User Image yony82 Posted - 04/25/24

$MYNZ Going to see some action in 10 mins probably

User Image axapol Posted - 04/24/24

@TrianglePlay2 @Predator777 @DDDiligence took some of my profit and moved on to $BLUE and $MYNZ

User Image Tbio64 Posted - 04/19/24

$MYNZ I hate fridays

User Image Tbio64 Posted - 04/19/24

$MYNZ new ath in progress

User Image Tbio64 Posted - 04/19/24

$MYNZ so... Time to go up.....

User Image DonCorleone77 Posted - 04/09/24

$MYNZ Mainz Biomed reports 2023 EPS ($1.62), consensus ($1.69) Reports revenue $895,479, consensus $940,000. "This past fiscal year represented an important period of progress for the Company highlighted by reporting results from our groundbreaking ColoFuture and eAArly DETECT studies which demonstrated extraordinary statistical significance for colorectal cancer detection and advanced adenomas, a type of pre-cancerous polyp which are considered precursors to colorectal cancer," commented Guido Baechler, Chief Executive Officer of Mainz Biomed. "This outstanding outcome positions our much-anticipated ReconAAsense pivotal FDA PMA study to be optimally designed to evaluate a best-in-class self-administered CRC screening tool which if successful, will be the gold standard stool-based diagnostic for this deadly disease. As we make final preparations to initiate ReconAAsense's patient enrollment, which remains on track to begin later this year..."

User Image Stock_Titan Posted - 04/09/24

$MYNZ Mainz Biomed Reports Full Year 2023 Financial Results https://www.stocktitan.net/news/MYNZ/mainz-biomed-reports-full-year-2023-financial-e667pp2a97hj.html

User Image Orlandotrader Posted - 04/06/24

$MYNZ Need this US Clinical Trial

Analyst Ratings
Cantor Fitzgerald Neutral Apr 12, 24
HC Wainwright & Co. Buy Mar 6, 24
Cantor Fitzgerald Neutral Nov 21, 23
HC Wainwright & Co. Buy Nov 20, 23
Cantor Fitzgerald Overweight Sep 26, 23
HC Wainwright & Co. Buy Sep 22, 23
Cantor Fitzgerald Overweight Sep 14, 23
Cantor Fitzgerald Overweight Aug 22, 23
HC Wainwright & Co. Buy Aug 18, 23